Cometriq (Cabozantinib-S-Malate): Uses, Side Effects & Warnings

• Cometriq is a targeted therapy approved for specific advanced cancers, including medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
• It works by inhibiting multiple tyrosine kinases that play a role in tumor growth, angiogenesis, and metastasis.
• Patients must adhere strictly to prescribed dosages and administration instructions, often involving taking the medication on an empty stomach.
• Common side effects include fatigue, diarrhea, nausea, and hypertension, while serious risks involve hemorrhage, gastrointestinal perforations, and thrombotic events.
• Close monitoring by a healthcare professional is essential throughout treatment to manage side effects and ensure patient safety.

What is Cometriq (Cabozantinib-S-Malate) Used For?

Cometriq (Cabozantinib-S-Malate) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor indicated for the treatment of specific advanced cancers. It works by blocking the activity of several RTKs, including MET, VEGFR2, and AXL, which are known to be involved in tumor angiogenesis (formation of new blood vessels that feed tumors), tumor growth, and metastasis. This targeted approach helps to slow or stop the progression of cancer cells.

The primary Cometriq uses and dosage indications include the treatment of progressive, metastatic medullary thyroid cancer (MTC). Additionally, it is approved for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. More recently, Cometriq has also been approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. These indications highlight its broad utility in managing various aggressive malignancies, offering a crucial therapeutic option for patients with limited alternatives.

Cometriq (Cabozantinib-S-Malate) Dosage and Administration

The precise Cometriq (Cabozantinib-S-Malate) dosage and administration schedule are critical for its efficacy and safety. Cometriq is available as tablets and is typically taken orally once daily. For most indications, the recommended starting dose is 60 mg orally once daily. It is crucial to take Cometriq on an empty stomach, at least 2 hours after and 1 hour before a meal. Patients should swallow the tablets whole and not crush, chew, or split them, as this can affect drug absorption and potentially lead to altered exposure.

Healthcare providers often provide a detailed Cabozantinib-S-Malate patient guide to ensure proper adherence. Dosage adjustments may be necessary based on individual patient tolerance and the occurrence of adverse reactions. For instance, if a patient experiences severe side effects, the dose may be reduced, or treatment may be temporarily interrupted. It is imperative that patients do not alter their dose or stop taking the medication without consulting their doctor. Regular monitoring and communication with the healthcare team are vital to manage treatment effectively and safely. This comprehensive Cometriq drug information emphasizes the importance of strict adherence to prescribed guidelines.

Potential Side Effects of Cabozantinib

Like all potent medications, Cabozantinib can cause a range of side effects, some of which can be serious. Understanding these potential reactions is crucial for patients and healthcare providers to manage treatment effectively. Common side effects are generally manageable but can impact a patient’s quality of life. Serious side effects, though less frequent, require immediate medical attention.

Common Cabozantinib side effects often include:

• Fatigue and weakness
• Diarrhea or constipation
• Nausea and vomiting
• Decreased appetite and weight loss
• Hand-foot syndrome (palmar-plantar erythrodysesthesia), characterized by redness, swelling, and pain on the palms of the hands and soles of the feet
• Hypertension (high blood pressure)
• Changes in taste
• Hair color changes or hair loss
• Abdominal pain
• Oral pain or inflammation (stomatitis)

More serious side effects, which necessitate prompt medical evaluation, include hemorrhage (bleeding), gastrointestinal perforations and fistulas (abnormal connections between organs), arterial thrombotic events (blood clots in arteries leading to heart attack or stroke), proteinuria (protein in the urine), osteonecrosis of the jaw (bone death in the jaw), and wound complications. Patients should report any unusual or severe symptoms to their healthcare provider immediately. For example, severe abdominal pain, persistent bleeding, or chest pain are urgent concerns. According to the National Cancer Institute, managing these side effects proactively is key to maintaining treatment continuity and patient well-being.

Cometriq Warnings and Precautions

There are several significant Cometriq warnings and precautions that patients and healthcare professionals must be aware of before and during treatment with Cometriq (Cabozantinib-S-Malate). These warnings are in place due to the potential for serious and life-threatening adverse events associated with the medication. Close monitoring and proactive management are essential to mitigate these risks.

One critical concern is the risk of hemorrhage, which can be severe and even fatal. Patients with a history of bleeding disorders or those on anticoagulant therapy require careful assessment. Gastrointestinal perforations and fistulas are also serious risks, particularly in patients with a history of diverticulitis or prior abdominal radiation. Arterial thrombotic events, such as heart attack or stroke, have occurred in patients treated with Cometriq, necessitating caution in individuals with cardiovascular risk factors. Hypertension is a common side effect and must be controlled with appropriate antihypertensive therapy; if blood pressure remains uncontrolled despite medication, Cometriq may need to be interrupted or discontinued.

Other important precautions include proteinuria, which requires regular monitoring of urine protein levels, and osteonecrosis of the jaw, especially in patients with a history of dental problems or those receiving bisphosphonates. Wound complications, including delayed wound healing, can occur, and Cometriq should be temporarily discontinued prior to planned surgery. Thyroid dysfunction, including hypothyroidism, is also a known risk, requiring baseline and periodic monitoring of thyroid function. Furthermore, Cometriq can cause embryo-fetal toxicity, and women of reproductive potential should be advised of the potential risk to a fetus and use effective contraception during treatment and for at least 4 months after the last dose. Men with female partners of reproductive potential should also use effective contraception. These comprehensive warnings underscore the importance of a thorough medical history and ongoing clinical vigilance throughout the course of treatment.

Frequently Asked Questions About Cometriq

How does Cometriq work to fight cancer?

Cometriq (Cabozantinib-S-Malate) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor. It works by blocking the activity of several specific proteins (tyrosine kinases) that are crucial for cancer cell growth, survival, and the formation of new blood vessels that supply tumors. By inhibiting these pathways, Cometriq helps to slow down or stop the proliferation of cancer cells and reduce tumor size, particularly in medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. This targeted approach aims to disrupt the mechanisms that drive cancer progression.

What should I discuss with my doctor before starting Cometriq?

Before starting Cometriq, it is vital to have a comprehensive discussion with your doctor. You should inform them about all your medical conditions, especially any history of bleeding, blood clots, high blood pressure, gastrointestinal problems (like perforations or fistulas), dental issues, or thyroid disorders. Disclose all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, as these can interact with Cometriq. Also, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, due to the potential risks to a fetus or infant.

Can Cometriq be taken with food?

No, Cometriq (Cabozantinib-S-Malate) should not be taken with food. It is crucial to take Cometriq on an empty stomach to ensure proper absorption and effectiveness. This means you should take your dose at least 2 hours after eating any food and wait at least 1 hour before consuming any food. Adhering to these specific timing instructions is essential for the medication to work as intended. Always follow your doctor’s instructions precisely regarding how and when to take your Cometriq dose.